Belgium's Confo Therapeutics, another company hoping to tap into the mad rush in the pharma industry for drugs for weight loss, made around €60 million (around $65 million) from its Series B ...

A significant player in the Belgian biotech industry, Confo Therapeutics has devised a technology to keep GPCRs stable, enabling the mass screening and identification of GPCRs in different diseases.

It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two ...

It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two ...

Viking Therapeutics Inc (NASDAQ:VKTX) reported positive data from four clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis. The Phase II VENTURE trial for VK2735 ...

End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

Seaport Therapeutics, the startup launched earlier this year by the team behind Karuna Therapeutics, has raised another $225 million just six months after its most recent fundraising round.

LOS ANGELES--(BUSINESS WIRE)--Terray Therapeutics, a biotechnology company improving human health by transforming the speed, cost, and success rate of small molecule drug development using ...